| Q46038854 | Activated interferon system in healthy homosexual men. |
| Q30457345 | Antiviral chemotherapy and prophylaxis of viral respiratory disease |
| Q39309529 | Antiviral therapy with small particle aerosols |
| Q36070394 | Antiviral therapy: current concepts and practices |
| Q39460438 | Biochemistry and clinical applications of ribavirin |
| Q38367260 | Clinical pharmacokinetics of inhaled antimicrobials. |
| Q39659099 | Clinical review of ribavirin. |
| Q35122262 | Common community respiratory viruses in patients with cancer: more than just "common colds". |
| Q33950804 | Community respiratory virus infections in immunocompromised patients with cancer |
| Q34047338 | Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors |
| Q40698854 | Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial |
| Q35540919 | Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections |
| Q41644488 | Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats |
| Q35251131 | Hemodialysis clearance of intravenously administered ribavirin |
| Q35244780 | High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay |
| Q34894660 | How to approach and treat viral infections in ICU patients |
| Q26822988 | Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead |
| Q30367819 | MegaRibavirin aerosol for the treatment of influenza A virus infections in mice |
| Q50590975 | Nebulised ribavirin for influenza B viral pneumonia in a ventilated immunocompromised adult. |
| Q34807255 | Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy |
| Q30228856 | Pandemic and seasonal influenza: therapeutic challenges |
| Q33812419 | Perspectives for the treatment of infections with Flaviviridae |
| Q35289449 | Pharmacokinetics of ribavirin aerosol in mice |
| Q37901455 | Pneumonias in adults due to mycoplasma, chlamydiae, and viruses |
| Q34074998 | Recent advances in diagnosis and therapy of human papillomaviruses |
| Q39178651 | Ribavirin attenuates the respiratory immune responses to influenza viral infection in mice |
| Q44827691 | Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level |
| Q39818236 | Ribavirin small-particle-aerosol treatment of influenza B virus infection |
| Q37977579 | Screening for new agents |
| Q48585293 | Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America |
| Q33996838 | Targeting drugs to the brain by redox chemical delivery systems. |
| Q39563538 | The future of antiviral chemotherapy |
| Q43177533 | Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine |
| Q91908704 | Viral pneumonia in children |